Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026)
Elanco Animal Health (ELAN) reported Non-Current Assets of $9.6 billion for Q1 2026, up 1.44% on a YoY basis from $9.5 billion in Q1 2025, and down 2.65% sequentially from $9.9 billion in Q4 2025.
Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Non-Current Assets data on file, last reported at $9.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 1.44% year-over-year to $9.6 billion; the trailing twelve-month figure through Mar 2026 stood at $39.7 billion (up 2.99% YoY), and the FY2025 full-year result was $9.9 billion, up 5.33% from the prior year.
- Non-Current Assets declined to $9.6 billion in Q1 2026, from $9.9 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $13.1 billion in Q1 2022 to a low of $9.4 billion in Q4 2024.
- A 5-year average of $10.8 billion and a median of $10.1 billion in 2025 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets retreated 19.69% in 2024 and climbed 5.33% in 2025, its largest moves.
- Tracing ELAN's Non-Current Assets over 5 years: stood at $12.2 billion in 2022, then decreased by 10.29% to $11.0 billion in 2023, then dropped by 14.2% to $9.4 billion in 2024, then grew by 5.33% to $9.9 billion in 2025, then slipped by 2.65% to $9.6 billion in 2026.
- Business Quant data shows ELAN's Non-Current Assets at $9.6 billion in Q1 2026, $9.9 billion in Q4 2025, and $10.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 670.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.64 Bn |
| Dec 31, 2025 | 9.90 Bn |
| Sep 30, 2025 | 10.06 Bn |
| Jun 30, 2025 | 10.13 Bn |
| Mar 31, 2025 | 9.50 Bn |
| Dec 31, 2024 | 9.40 Bn |
| Sep 30, 2024 | 9.92 Bn |
| Jun 30, 2024 | 9.75 Bn |
| Mar 31, 2024 | 9.97 Bn |
| Dec 31, 2023 | 10.96 Bn |
| Sep 30, 2023 | 10.78 Bn |
| Jun 30, 2023 | 12.14 Bn |
| Mar 31, 2023 | 12.22 Bn |
| Dec 31, 2022 | 12.21 Bn |
| Sep 30, 2022 | 11.79 Bn |
| Jun 30, 2022 | 12.29 Bn |
| Mar 31, 2022 | 13.06 Bn |
| Dec 31, 2021 | 13.20 Bn |
| Sep 30, 2021 | 13.41 Bn |
| Jun 30, 2021 | 13.40 Bn |